Data / Form D filings / ENB Therapeutics, Inc.
ENB Therapeutics, Inc.: Form D filings
ENB Therapeutics, Inc., a biotechnology company in New York, NY, filed 4 Form D notices with the SEC between 2018 and 2023. The latest, on October 3, 2023, reports $225,000 sold of a $1 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- C/O LAUNCHLABS, 430 E 29th St., 14TH Floor, New York, NY, 10016
- Phone
- (212) 792-2317
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2018
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1753420
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 3, 2023 | New notice | $1,000,000 | $225,000 | $775,000 | 3 | Sep 22, 2023 | sec.gov |
| Jan 11, 2021 | New notice | $2,600,000 | $1,282,500 | $1,317,500 | 3 | Jan 7, 2021 | sec.gov |
| Feb 13, 2020 | Amendment | $9,094,584 | $8,094,584 | $1,000,000 | 17 | Sep 7, 2018 | sec.gov |
| Sep 21, 2018 | New notice | $9,094,584 | $2,294,572 | $6,800,012 | 17 | Sep 7, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Sumayah Jamal | Executive Officer, Director | |
| Barbara Schilberg | Director | |
| Stuart Hwang | Director | |
| Walter Olesiak | Director | |
| Albert Sokol | Executive Officer |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Oct 2, 2023 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ENB Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.